



NovaSterilis Receives Qualifying Therapeutic Discovery Project Grant for Sterilization of Biomedical Materials

ITHACA, NY, November 8, 2010

NovaSterilis, a Lansing NY company, was awarded a \$207,916 grant through the Qualifying Therapeutic Discovery Project enacted as part of the Patient Protection and Affordable Care Act of 2010. This funding is intended for companies with fewer than 250 employees targeting improved therapies, products, process or technology to further the delivery or administration of therapies. NovaSterilis is developing a novel sterilization technology for biomedical materials, including products unsuitable for the current methodologies of steam, irradiation or gas sterilization (EtO). The NovaSterilis process utilizes supercritical CO₂ to achieve a Sterility Assurance Level of 10⁻⁶ or the potential for 1 bacterial spore in a million to survive the process.

“NovaSterilis is pleased and excited that the Department of Health and Human Services recognizes the need for sterile allograft tissue,” said David C. Burns, President and CEO NovaSterilis. “This grant and other NIH/NSF grants play a vital role in the development of new technologies that enhance the lives and provide valuable jobs to American citizens. The new technology will improve patient safety, reduce the potential for infection and likely decrease healing time for the 1.5 million patients who receive allograft transplants yearly.

About NovaSterilis

NovaSterilis currently markets supercritical carbon dioxide terminal sterilization technologies, and equipment built to support applications of their supercritical carbon dioxide technology platform. The supercritical or fluid phase, of CO₂ occurs at low pressure (72.9 atm) and moderate temperatures (31.1° C). Supercritical CO₂ retains advantageous properties of the gas and liquid phases of carbon dioxide making it an ideal fluid for manufacturing processes. The company currently markets the Nova 2200, a 20 liter fully automated supercritical CO₂ terminal sterilization chamber and is developing an 80 liter unit.

NovaSterilis, a privately held biotechnology company located in Lansing New York, is the recipient of a 2007 Presidents Green Chemistry Award presented by the Environmental Protection Agency.

For more information on NovaSterilis and supercritical carbon dioxide visit www.novasterilis.com

The foregoing release contains forward-looking statements that can be identified by language such as “produced” and “immediate”, for example, or by express or implied statements regarding the value of this technology. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause future results with supercritical carbon dioxide technologies to differ from any previous research. There can be no guarantee that SCCO₂ will produce marketed clinical vaccines for sale in any market. Nor can there be any guarantee that the use of SCCO₂ to produce therapeutic vaccines will achieve any particular levels of revenue in the future.